Close
FINDING CURES TOGETHER<sup>SM</sup>

Pancreatic Cancer: Advances in Science and Clinical Care

​Program*

Friday, Sept. 21

Registration
3-7 p.m.


Welcome and Keynote Lectures

6:30-8:30 p.m.

Welcome from Cochairs
Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Welcome from Lead Supporters
Kerri Kaplan, Lustgarten Foundation, Woodbury, New York
Julie M. Fleshman, Pancreatic Cancer Action Network, Manhattan Beach, California

Precision medicine for pancreas cancer: New approaches from old
Ben Z. Stanger, Abramson Cancer Center of University of Pennsylvania, Philadelphia, Pennsylvania

Keynote Lecture

Andrew H. Ko, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California


Opening Reception

8:30-10 p.m.


Saturday, Sept. 22

Breakfast and Networking Roundtables
7:30-8:30 a.m.


Plenary Session 1: Imaging/Diagnostics
8:30-10 a.m.
Session Chair: Brian M. Wolpin, Dana-Farber Cancer Institute, Boston, Massachusetts

Title to be announced
Elliot K. Fishman, Johns Hopkins Hospital, Baltimore, Maryland

Immunologic properties of biophysical subtypes of pancreatic cancer: Implications for therapeutic selection
Eugene Koay, The University of Texas MD Anderson Cancer Center, Houston, Texas

Using artificial intelligence to extract latent biomarkers from clinical imaging of the pancreas
Michael H. Rosenthal, Dana-Farber Cancer Institute, Boston, Massachusetts

Break
10-10:30 a.m.


Plenary Session 2: The Changing Practice of Genetic Testing
10:30 a.m.-12:30 p.m.
Session Chair: Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, Minnesota

Risk estimates for pancreatic cancer predisposition genes
Fergus J. Couch, Mayo Clinic, Rochester, Minnesota

Title to be announced
Maeve Lowery, Trinity College Dublin, Dublin, Ireland

Genetic predisposition to pancreatic cancer: Who should be tested, and how?
Elena M. Stoffel, University of Michigan, Ann Arbor, Michigan

Identification and management of healthy individuals with pancreatic cancer susceptibility gene mutations
Sapna Syngal, Dana-Farber Cancer Institute, Boston, Massachusetts


Poster Session A / Lunch
12:30-3 p.m.


Plenary Session 3: Blood-Based Early Detection
3:15-4:45 p.m.
Session Chair: Brian M. Wolpin, Dana-Farber Cancer Institute, Boston, Massachusetts

Multi-analyte blood test for the detection of cancer
Nickolas Papadopoulos, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Developing a biomarker panel to detect early-stage pancreatic cancer
Kenneth S. Zaret, University of Pennsylvania, Philadelphia, Pennsylvania

Title to be announced
Anirban Maitra, The University of Texas MD Anderson Cancer Center, Houston, Texas


Break
4:45-5 p.m.


Plenary Session 4: Immunology and Immunotherapy
5-6:30 p.m.
Session Chair: Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Title to be announced
Manuel Hidalgo

Title to be announced
Vinod Balachandran, Memorial Sloan Kettering Cancer Center, New York, New York

Innate and adaptive immunity in the tumor microenvironment of pancreas cancer
David C. Linehan, University of Rochester, Rochester, New York


Evening Off / Dinner on Own
6:30 p.m.-


Sunday, Sept. 23

Breakfast and Networking Roundtables
7:30-8:30 a.m.


Plenary Session 5: Tumor Microenvironment
8:30-10 a.m.
Session Chair: Ronald M. Evans, Salk Institute for Biological Studies, La Jolla, California

Title to be announced
Michael A. Hollingsworth, UNMC Eppley Institute for Research in Cancer, Omaha, Nebraska

Fibroblast heterogeneity in pancreatic cancer
David A. Tuveson, Cold Spring Harbor Laboratory Cancer Center, Cold Spring Harbor, New York

Title to be announced
Sunil R. Hingorani, Fred Hutchinson Cancer Research Center, Seattle, Washington

Break
10-10:30 a.m.


Plenary Session 6: RAS/Signaling/Oncogenes
10:30 a.m.-12:30 p.m.
Session Chair: Manuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Title to be announced
Raghu Kalluri, The University of Texas MD Anderson Cancer Center, Houston, Texas

Treatment of oncogenic activation of ERK in human cancer
Neal Rosen, Memorial Sloan Kettering Cancer Center, New York, New York

KRas-mediated regulation of the tumor microenvironment
Ronald A. DePinho, The University of Texas MD Anderson Cancer Center, Houston, Texas

Title to be announced
Mariano Barbacid, Spanish National Cancer Research Center, Madrid, Spain


Free Time / Lunch on Own
12:30-2:30 p.m.


Plenary Session 7: Metabolism and Metabolomics
2:45-4:45 p.m.
Session Chair: Ronald M. Evans, Salk Institute for Biological Studies, La Jolla, California

Title to be announced
Ronald M. Evans

Title to be announced
Nabeel M. Bardeesy, Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Targeting cysteine metabolism in pancreatic cancer
Kenneth P. Olive, Columbia University Irving Comprehensive Cancer Center, New York, New York

Title to be announced
Giulio F. Draetta, The University of Texas MD Anderson Cancer Center, Houston, Texas


Poster Session B / Reception
5-7:30 p.m.


Evening Off/Dinner on Own
7:30 p.m.-


Monday, Sept. 24

Breakfast

7:30-8:30 a.m.


Plenary Session 8: Precision Medicine
8:30-10 a.m.
Session Chair: Steven D. Leach, Dartmouth Norris Cotton Cancer Center, Lebanon, New Hampshire

Title to be announced
Andrew Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts

Title to be announced
Senthil K. Muthuswamy, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Mixed messages: Altered mRNA splicing provides a new therapeutic vulnerability in p53-mutant pancreatic cancer
Lusia Escobar-Hoyos, Memorial Sloan Kettering Cancer Center, New York, New York

Break
10-10:15 a.m.


Plenary Session 9: Local-Regional Therapies / Management of Local Disease
10:15-11:45 a.m.
Session Chair: Steven D. Leach, Dartmouth Norris Cotton Cancer Center, Lebanon, New Hampshire

Pancreas SBRT: Ablation versus immune potentiation
Joseph M. Herman, The University of Texas MD Anderson Cancer Center, Houston, Texas

Why operable pancreatic cancer is the best model for translational research: Treatment sequencing, assessment of response, and results with innovative multimodality therapy
Douglas B. Evans, Medical College of Wisconsin, Milwaukee, Wisconsin

New directions in adjuvant and neoadjuvant therapy for pancreas cancer
Eileen O’Reilly, Memorial Sloan Kettering Cancer Center, New York, New York


Panel Discussion on Clinical Trials
11:45 a.m.-12:45 p.m.
Moderator: Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, Minnesota

Panelists: Andrea Wang-Gillam, Washington University in St.Louis, St. Louis, Missouri

Additional panelists to be announced


Departure
12:45 p.m.


*Program as of June 22, 2018. Additional speakers to be announced.

Top of page